OTHER GROUP COMPANIES
market

Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene Cream, 0.005%

Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene Cream, 0.005%

May 04, 2015 12:00 IST | capital market
Glenmark Pharmaceuticals announced that Glenmark Pharmaceuticals Inc., United States has been granted tentative approval by the United States Food & Drug Administration for Calcipotriene Cream, 0.005%, the therapeutic equivalent of Dovonex Topical Cream, 0.005% of Leo Pharma A/S. Glenmark will market this product upon receiving final approval of its Calcipotriene Cream, 0.005% ANDA. The patents listed in the Orange Book of Dovonex Cream are scheduled to expire on 19 June 2015.

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Worth 5,000

FEATURED ARTICLE

BLOGS

Open Demat Account
  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity